Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops and delivers innovative treatments for serious neurological and neurological diseases. It has a market value of $27.7 billion.
Companies valued at $10 billion or more are generally classified as “large-cap stocks,” and Biogen fits the label perfectly, with its market cap exceeding that threshold, indicating its size, influence, and dominance in the drugmaker-general industry. Beyond its core neurology focus, the company is actively expanding its pipeline across immunology and rare diseases, leveraging cutting-edge approaches such as antisense oligonucleotides (ASOs) to target high unmet medical needs.
The healthcare company is currently trading 5.5% below its 52-week high of $202.41, reached on February 6. Shares of BIIB have gained 10.8% over the past three months, underperforming the State Street Healthcare Select Sector SPDR ETF ( XLV ) during the same time frame.
Furthermore, on a YTD basis, BIIB shares are up 8.6% compared to XLV’s 1.4% decline. Over the long term, Biogen has gained 33.1% over the past 52 weeks, notably ahead of XLV’s 4.6% rise over the same time frame.
Confirming its bullish trend, BIIB has been trading above its 200-day moving average since late August and has remained above its 50-day moving average with little change since mid-August.
On February 6, BIIB shares advanced 8.5% after stronger-than-expected Q4 earnings were released. The company’s revenue fell 7.1% year over year to $2.3 billion, but beat analysts’ estimates of $2.2 billion. Meanwhile, its adjusted EPS came in at $1.99, handily exceeding consensus expectations of $1.63. Management credited the quarter’s performance to strong momentum in its new product portfolio, particularly Lacambi, Skyclaries, Zorzoi, and Qalsodi, which together generated more than $1 billion in annual revenue.
BIIB’s rival, Amgen Inc. ( AMGN ), which has risen 18.4% over the past 52 weeks. However, this lags behind AMGN’s 15.3% YTD increase.
Given Biogen’s recent good performance, analysts are moderately optimistic about its prospects. The stock has a consensus rating of “average buy” from the 35 analysts that cover it, and an average price target of $206.66 suggests an 8.6% premium to its current price level.
As of the date of publication, Niharika Jain held no positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. This article was originally published on Barchart.com
